Success in drug development begins with a strong foundation.
Early Phase Healthy Volunteer studies are a critical first step – complex, fast-paced, and requiring expert precision.
Our dedicated Early Phase team brings deep expertise and rigorous operational oversight to every study. With proven governance and seamless execution, we help you navigate the complexities and minimize your risk to accelerate your path forward.
Focus on your future while we handle the details.
Our team has your best interests in mind and can ensure your development journey begins with precision and efficiency.
Strong Relationships Drive Strong Results
At Emerald Clinical Trials, we believe that relationships are the foundation of success. It’s our connections, with sites, sponsors, and each other, that keep studies on track, even in a highly competitive environment. That’s what keeps our team united in a shared purpose. And its what makes us the right CRO for your Early Phase studies. When you work with Emerald, you gain more than a service provider, you gain a committed partner who goes the extra mile to help you succeed.
The Australian Advantage Can Put Money in Your Pocket for Future Development
Conducting Early Phase studies in Australia comes with a major financial benefit.
The Australia R&D tax rebate of up to 43.5% is refundable for eligible small companies, who can receive a cash refund, not just a tax offset. This valuable incentive can help fund your ongoing development or extend your financial runway. Emerald Clinical can connect you with experienced tax professionals who specialize in R&D claims. They ensure your submissions are accurate, compliant and optimized for maximum return.
We don’t just run trials—we build partnerships. Our goal is to understand your science, align with your vision, and accelerate your path to success.
Tamara Murdock
Why Emerald Clinical?
We shape your Early Phase strategy to align clinical, regulatory, and commercial goals – setting the stage for long-term success.
Strategic Design Matters
From innovation to impact, our Early Phase team delivers the insight and experience to guide your breakthrough therapies forward.
Your Gateway to the Future
We start with the finish line in mind to expertly navigate your program seamlessly through Phases II/III to a successful NDA submission.
Transition Across the Globe
With strong APAC ties, KOL relationships, and boots on the ground globally, we enable effortless worldwide growth.
Full-Service Capability
We offer a full spectrum of integrated services, from regulatory strategy, medical monitoring, biostats, scientific advisory, and site operations.
De-Risk, Accelerate, and Amplify
Prevent delays from day one. Every week saved accelerates your path to market — and earlier market entry can translate into millions in savings.
Real Collaboration — Long Term Value
At Emerald Clinical, your success drives us. . Our mission is to bring effective treatments to patients worldwide – without delay. faster.
Contact Us to Find Out How We Can Help Shape Your Clinical Design
Meet our Expert
Tamara Murdock
Tamara has over 25 years of clinical research experience in pharmacology and therapeutic areas including oncology, metabolic disorders, cardiology, and dermatology. A distinguished leader in Early Phase, she has worked in a Phase I unit in Australia and with Australian-based CROs. Her expertise and deep passion guide clients to accelerate their early-phase research and transform promising ideas into groundbreaking medical advancements. As Global Head of Early Phase Research, she is dedicated to ensuring that studies are conducted with precision, efficiency, and the highest scientific and ethical standards. Her commitment to excellence and strategic vision make her a trusted partner in bringing new therapies to life.
Together, we bring a uniquely integrated lens to every phase of development—from preclinical strategy to Phase III trial optimization.
Ready to Build the Next Breakthrough in Early Phase Care?
Partner with a leading CRO that delivers evidence, experience, and precision at every stage of your program.
The future of renal drug development belongs to those who design smarter from day one. Planning your next program? Don’t go it alone.
